Warning: The NCBI web site requires JavaScript to function. more...
The Quit Benefits Model: a Markov model for assessing the health benefits and health care cost savings of quitting smoking.
Hurley SF, Matthews JP.
Cost Eff Resour Alloc. 2007 Jan 23;5:2.
Related citations
Final Report on Carcinogens Background Document for Formaldehyde.
National Toxicology Program.
Rep Carcinog Backgr Doc. 2010 Jan;(10-5981):i-512.
Cost-effectiveness of the Australian National Tobacco Campaign.
Tob Control. 2008 Dec;17(6):379-84. Epub 2008 Aug 21.
Final Report on Carcinogens Background Document for Styrene.
Rep Carcinog Backgr Doc. 2008 Sep;(8-5978):i-398.
A model for cost-effectiveness analyses of smoking cessation interventions applied to a Quit-and-Win contest for mothers of small children.
Johansson PM, Tillgren PE, Guldbrandsson KA, Lindholm LA.
Scand J Public Health. 2005;33(5):343-52.
Cost-utility analysis of varenicline versus existing smoking cessation strategies using the BENESCO Simulation model: application to a population of US adult smokers.
Howard P, Knight C, Boler A, Baker C.
Pharmacoeconomics. 2008;26(6):497-511.
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
Clegg A, Scott DA, Sidhu M, Hewitson P, Waugh N.
Health Technol Assess. 2001;5(32):1-195. Review.
'Cut down to quit' with nicotine replacement therapies in smoking cessation: a systematic review of effectiveness and economic analysis.
Wang D, Connock M, Barton P, Fry-Smith A, Aveyard P, Moore D.
Health Technol Assess. 2008 Feb;12(2):iii-iv, ix-xi, 1-135. Review.
The SmokingPaST Framework: illustrating the impact of quit attempts, quit methods, and new smokers on smoking prevalence, years of life saved, medical costs saved, programming costs, cost effectiveness, and return on investment.
O'Donnell MP, Roizen MF.
Am J Health Promot. 2011 Sep-Oct;26(1):e11-23.
Cost effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a lifetime model.
Millar JA, Millward MJ.
Pharmacoeconomics. 2007;25(5):429-42.
Cost effectiveness of varenicline versus bupropion and unaided cessation for smoking cessation in a cohort of Finnish adult smokers.
Linden K, Jormanainen V, Linna M, Sintonen H, Wilson K, Kotomäki T.
Curr Med Res Opin. 2010 Mar;26(3):549-60.
Dynamic effects of smoking cessation on disease incidence, mortality and quality of life: The role of time since cessation.
Hoogenveen RT, van Baal PH, Boshuizen HC, Feenstra TL.
Cost Eff Resour Alloc. 2008 Jan 11;6:1.
Predicting the impact of population level risk reduction in cardio-vascular disease and stroke on acute hospital admission rates over a 5 year period--a pilot study.
Whitfield MD, Gillett M, Holmes M, Ogden E.
Public Health. 2006 Dec;120(12):1140-8. Epub 2006 Nov 3.
Cost-effectiveness analysis of screening for lung cancer with low dose spiral CT (computed tomography) in the Australian setting.
Manser R, Dalton A, Carter R, Byrnes G, Elwood M, Campbell DA.
Lung Cancer. 2005 May;48(2):171-85. Epub 2005 Jan 4.
Lung cancer screening with helical computed tomography in older adult smokers: a decision and cost-effectiveness analysis.
Mahadevia PJ, Fleisher LA, Frick KD, Eng J, Goodman SN, Powe NR.
JAMA. 2003 Jan 15;289(3):313-22.
Clinical effectiveness and cost-effectiveness of laparoscopic surgery for colorectal cancer: systematic reviews and economic evaluation.
Murray A, Lourenco T, de Verteuil R, Hernandez R, Fraser C, McKinley A, Krukowski Z, Vale L, Grant A.
Health Technol Assess. 2006 Nov;10(45):1-141, iii-iv. Review.
Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease.
Spencer M, Briggs AH, Grossman RF, Rance L.
Pharmacoeconomics. 2005;23(6):619-37.
Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J, Jones J, Takeda A, Davidson P, Price A.
Health Technol Assess. 2006 Aug;10(28):iii-iv, xi-xiv, 1-183. Review.
Cost-effectiveness of smoking cessation to prevent age-related macular degeneration.
Hurley SF, Matthews JP, Guymer RH.
Cost Eff Resour Alloc. 2008 Sep 11;6:18.
Encouraging smokers to quit: the cost effectiveness of reimbursing the costs of smoking cessation treatment.
Kaper J, Wagena EJ, van Schayck CP, Severens JL.
Pharmacoeconomics. 2006;24(5):453-64.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on